Friday, November 18, 2011 9:32:07 PM
PR released on Nov 7:
SAN FRANCISCO, CA--(Marketwire -11/07/11)- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD - News) announced today that Glass, Lewis & Co., a leading independent proxy advisory firm, has recommended that Poniard shareholders vote "FOR" all proposals listed in the Company's proxy statement materials, including the proposal related to the issuance of stock in connection with Poniard's proposed merger with ALLOZYNE, Inc. and the proposal to effect a 1-for-40 reverse stock split of Poniard's outstanding common stock.
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM